Can You Ever Stop — Targeted Therapy?

The tiredness you feel is real, and it is worth saying plainly that treatment fatigue is a legitimate reason to have this conversation with your oncologist. But stopping without medical review puts you at risk of the disease returning quickly — and in some cases more aggressively. The better route is to raise this directly: ask what the evidence says for your specific cancer, whether your response meets any stopping criteria, and what the monitoring plan would look like. That conversation may not end with a stopping plan, but it is the right conversation to have rather than making the decision alone.

The people you have read about almost certainly have CML and have been on treatment for years with a deep molecular response — a very specific situation that does not apply to most patients on targeted therapy. Reports in the news or on patient forums rarely mention the cancer type, the depth of response, or the monitoring protocol that made stopping safe in that case. Ask your oncologist to explain the specific reason stopping is not currently recommended for your situation. A clear answer to that question is reasonable to expect and ask for.

Treatment-free remission means the disease remains stable and below a defined threshold even without ongoing treatment. In CML it is a recognised clinical goal — not a cure, but a state where treatment can be paused safely under monitoring. It is not the same as being cured, and it requires ongoing tests to confirm the remission is holding. If the disease starts to return, treatment is restarted. The term is sometimes used loosely to describe any treatment pause, but in its precise meaning it refers to a carefully defined, monitored state supported by clinical evidence.

Deep molecular response is measured by a sensitive blood test that looks for the genetic signal of the cancer — in CML, the BCR-ABL signal. As treatment works, this signal falls. A deep molecular response means it has fallen to an extremely low and sustained level. The depth and the duration of that response together predict whether a stopping attempt is likely to succeed. A clear scan tells you the cancer is not visible on imaging; a deep molecular response tells you something more precise about what is happening at the cellular level.

In CML, the evidence does not suggest that a stopping attempt causes resistance on restart. Most patients whose disease returns after a stopping attempt respond well to the same treatment they were on before. This is the evidence for CML specifically, under supervised conditions. For other cancers on targeted therapy, the data on resistance after an unsupervised stop is limited, and this is one reason stopping outside a clinical trial or guideline-supported pathway carries additional unknowns.

The monitoring plan after stopping is typically more frequent than the schedule you were on while stable on treatment. In CML, tests for the molecular signal are done at short intervals — monthly to begin with, then less frequently as confidence in the remission grows. A rising signal on those tests triggers a decision about restarting, often before any symptom appears. For any cancer where a stopping trial might be considered, ask your oncologist to explain the specific tests, the intervals, and the level that would prompt restarting. Know this plan before anything changes.